A detailed history of Northern Trust Corp transactions in Esperion Therapeutics, Inc. stock. As of the latest transaction made, Northern Trust Corp holds 1,474,422 shares of ESPR stock, worth $3.64 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares
1,474,422
Previous 405,038 264.02%
Holding current value
$3.64 Million
Previous $899,000 170.52%
% of portfolio
0.0%
Previous 0.0%

Shares

30 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 13, 2024

BUY
$1.61 - $2.73 $1.72 Million - $2.92 Million
1,069,384 Added 264.02%
1,474,422 $2.43 Million
Q2 2024

Aug 14, 2024

BUY
$1.84 - $3.24 $177,304 - $312,209
96,361 Added 31.22%
405,038 $899,000
Q1 2024

May 14, 2024

BUY
$2.02 - $3.02 $145,609 - $217,693
72,084 Added 30.47%
308,677 $827,000
Q4 2023

Feb 13, 2024

BUY
$0.73 - $3.08 $5,754 - $24,279
7,883 Added 3.45%
236,593 $707,000
Q3 2023

Nov 13, 2023

BUY
$0.96 - $1.79 $64,780 - $120,789
67,480 Added 41.85%
228,710 $224,000
Q2 2023

Aug 11, 2023

SELL
$1.2 - $1.76 $618,110 - $906,561
-515,092 Reduced 76.16%
161,230 $224,000
Q1 2023

May 15, 2023

BUY
$1.46 - $7.3 $16,408 - $82,044
11,239 Added 1.69%
676,322 $1.08 Million
Q4 2022

Feb 13, 2023

BUY
$5.09 - $8.5 $422,851 - $706,137
83,075 Added 14.27%
665,083 $4.14 Million
Q3 2022

Nov 14, 2022

BUY
$5.45 - $8.13 $78,000 - $116,356
14,312 Added 2.52%
582,008 $3.9 Million
Q2 2022

Aug 12, 2022

BUY
$4.77 - $6.67 $199,653 - $279,179
41,856 Added 7.96%
567,696 $3.61 Million
Q1 2022

May 13, 2022

BUY
$3.34 - $5.56 $630,201 - $1.05 Million
188,683 Added 55.96%
525,840 $2.44 Million
Q4 2021

Feb 08, 2022

BUY
$4.81 - $11.92 $203,535 - $504,394
42,315 Added 14.35%
337,157 $1.69 Million
Q3 2021

Nov 15, 2021

SELL
$11.34 - $21.37 $204,641 - $385,643
-18,046 Reduced 5.77%
294,842 $3.55 Million
Q2 2021

Aug 13, 2021

BUY
$19.4 - $28.71 $154,482 - $228,617
7,963 Added 2.61%
312,888 $6.62 Million
Q1 2021

May 12, 2021

SELL
$25.12 - $36.89 $510,413 - $749,567
-20,319 Reduced 6.25%
304,925 $8.55 Million
Q4 2020

Feb 11, 2021

SELL
$24.2 - $35.76 $310,316 - $458,550
-12,823 Reduced 3.79%
325,244 $8.46 Million
Q3 2020

Nov 16, 2020

SELL
$31.18 - $52.71 $456,942 - $772,465
-14,655 Reduced 4.15%
338,067 $12.6 Million
Q2 2020

Aug 14, 2020

BUY
$30.04 - $51.31 $1.17 Million - $1.99 Million
38,789 Added 12.36%
352,722 $18.1 Million
Q1 2020

May 14, 2020

BUY
$27.44 - $73.84 $97,988 - $263,682
3,571 Added 1.15%
313,933 $9.9 Million
Q4 2019

Feb 14, 2020

SELL
$35.4 - $59.82 $271,872 - $459,417
-7,680 Reduced 2.41%
310,362 $18.5 Million
Q3 2019

Nov 13, 2019

BUY
$34.47 - $47.53 $872,780 - $1.2 Million
25,320 Added 8.65%
318,042 $11.7 Million
Q2 2019

Aug 13, 2019

BUY
$40.1 - $52.33 $107,828 - $140,715
2,689 Added 0.93%
292,722 $13.6 Million
Q1 2019

May 13, 2019

BUY
$40.11 - $53.57 $88,482 - $118,175
2,206 Added 0.77%
290,033 $11.6 Million
Q4 2018

Feb 12, 2019

SELL
$36.99 - $59.11 $12.5 Million - $20 Million
-338,812 Reduced 54.07%
287,827 $13.2 Million
Q3 2018

Nov 14, 2018

BUY
$40.74 - $51.41 $1.49 Million - $1.88 Million
36,535 Added 6.19%
626,639 $27.8 Million
Q2 2018

Sep 18, 2018

SELL
$36.2 - $76.4 $58,716 - $123,920
-1,622 Reduced 0.27%
590,104 $23.1 Million
Q2 2018

Aug 14, 2018

BUY
$36.2 - $76.4 $446,128 - $941,553
12,324 Added 2.13%
591,726 $23.2 Million
Q1 2018

May 09, 2018

BUY
$65.94 - $80.76 $331,348 - $405,819
5,025 Added 0.87%
579,402 $41.9 Million
Q4 2017

Feb 14, 2018

SELL
$43.47 - $67.43 $153,883 - $238,702
-3,540 Reduced 0.61%
574,377 $37.8 Million
Q3 2017

Nov 13, 2017

BUY
$43.8 - $52.77 $25.3 Million - $30.5 Million
577,917
577,917 $29 Million

Others Institutions Holding ESPR

About Esperion Therapeutics, Inc.


  • Ticker ESPR
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Drug Manufacturers—Specialty & Generic
  • Shares Outstandng 66,551,600
  • Market Cap $164M
  • Description
  • Esperion Therapeutics, Inc., a pharmaceutical company, develops and commercializes medicines for the treatment of patients with elevated low density lipoprotein cholesterol. Its lead product candidates are NEXLETOL (bempedoic acid) and NEXLIZET (bempedoic acid and ezetimibe) tablets for the treatment of patients with atherosclerotic cardiovascul...
More about ESPR
Track This Portfolio

Track Northern Trust Corp Portfolio

Follow Northern Trust Corp and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Northern Trust Corp, based on Form 13F filings with the SEC.

News

Stay updated on Northern Trust Corp with notifications on news.